Skip to main content

Table 5 Multivariable model of variables associated with receipt of two or more breast imaging exams in the 6–26 months after diagnosis among tested women (N = 731)

From: Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

 

OR

(95% CI)

P

Recurrence score

  

0.06

 Low or intermediate (ref)

   

 High

0.49

(0.23–1.03)

 

Age at diagnosis, years

  

0.08

 24–39

0.36

(0.14–0.90)

 

 40–49

1.18

(0.72–1.92)

 

 50–59 (ref)

   

 60–63

1.23

(0.69–2.19)

 

Stage

  

0.48

 I

1.22

(0.70–2.12)

 

 II (ref)

   

Chemotherapy

  

0.33

 Yes

   

 No (ref)

1.29

(0.77–2.15)

 

Histological grade

  

0.84

 1–2 (well/moderately differentiated) (ref)

   

 3 (poorly or not differentiated)

1.06

(0.58–1.95)

 

Nodal involvement

  

0.58

 N0 (ref)

   

 N1mic/N1

1.27

(0.54–2.99)

 

Surgery type

  

<0.001

 Breast-conserving surgery

3.75

  

 Unilateral mastectomy (ref)

   
  1. Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes